[Please keep these entries up to date! See the updating procedure at the end of this post.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: VRTX (timelines updated for Telaprevir and VX-222; entry for VX-813/VX-985 removed because I think the programs are dead).
ABT – Certriad PFDUFA date early Apr 2010 (NDA submitted 6/5/09).
ACHN – ACH-1625 HCV protease inhibitor: top-line results of all phase-1b cohorts Jan 2010 (first cohort reported 12/15/09); present full dataset Apr 2010 at EASL; start phase-2 trial (with or w/o a partner) 1H10. ACHN – ACH-1095 HCV NS4A inhibitor: submit pre-IND package to FDA 4Q09. (See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=41217537 for status of GILD partnership.) ACHN – Unnamed HCV compound with novel MoA: reveal initial details to investors 1H10.
Actelion – BUILD-3 phase-3 trial of Tracleer in IPF: PFS primary endpoint any day (guidance was Dec 2009).
AGN – Botox for migraine: sBLA submission done in late 3Q09 (not PR’d); no reply yet from FDA on possible priority review. AGN – Botox for spasticity: reply to FDA’s CRL submitted in Oct 2009 (not PR’s); Class-2 response from FDA 1H10.
AMLN – Exenatide LAR: PDUFA date early Mar 2010 (NDA submitted 5/5/09 and accepted for review 7/7/09).
ANDS – ANA598 phase-2 trial: safety and RVR data from 400mg arm: 1H10; SVR data from all arms: 2H10. (Safety and RVR data from 200mg arm was reported on 12/17/09.)
Bayer – Xarelto: see JNJ. Bayer – VEGF Trap-Eye: see REGN.
DNDN – Provenge BLA PDUFA date 5/1/10.
ELN – AAB-001 phase-3: final data mid-2011 (est.). (First patient dosed 12/21/07.) ELN – ELND005 for AD phase-2: final data 1H10 (est.) (The two highest doses were dropped due to toxicity on 12/15/09.)
GILD – GS9190 HCV non-nucleoside polymerase inhibitor: start phase-1/2 combination studies with GS9256 protease inhibitor 1H10. (The refocusing of the GS9190 program and the existence of GS9256 were disclosed on GILD’s 3Q09 CC: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42717806 .) GILD – Elvitegravir phase-3 vs Isentress: complete enrollment 4Q09. GILD – TMC278 + Truvada combo pill: complete bioequivalence studies and submit NDA/MAA 2H10 simultaneously with, or soon after, JNJ’s NDA/MAA submissions for standalone TMC278. GILD – ‘Quad’ and GS9350 phase-2 studies: report 48-week (final) data from ‘Quad’ vs Atripla study and GS9350 vs ritonavir study at unspecified medical conferences during 2010. (Bare-bones 24-week data from both studies were reported on 1/6/10.)
HGSI – Zalbin/Joulferon (Albuferon): PDUFA date Sep 2010 if standard review (BLA submitted 11/25/09; MAA submitted 12/15/09). HGSI – Benlysta in SLE: submit BLA/MAA early 2010. (Data from 2nd phase-3 trial reported 11/2/09.)
ITMN – ITMN-191: see Roche. ITMN – pirfenidone: FDA PDUFA date 5/4/10; MAA submission 1Q10. ITMN – ITMN-520 qD pirfenidone analog for IPF and other conditions: IND filing mid 2010..
JNJ – TMC278 for HIV: report phase-3 data early 2010; submit NDA/MAA mid 2010. (See GILD me TMC278 + Truvada combo pill.) JNJ – TMC278 + Truvada combo pill: see GILD. JNJ – Xarelto: reply to FDA’s CRL 4Q09. JNJ – PurTox botulinum toxin: submit BLA calendar 4Q10 after completion of two ongoing phase-3 trials. (First phase-3 trial reported positive data 10/1/08.) JNJ – Telaprevir: see VRTX.
MRK – Isentress sNDA for qD dosing: submission 2011. (Phase-3 trial called QDMRK started 4Q08: Isentress BID + Truvada vs Isentress qD + Truvada in first-line setting.)
NVS – FTY720 in RRMS: NDA and EU MAA to be submitted in late 2009. (Positive data from the FREEDOMS trial were reported on 9/30/09. The FREEDOMS trial plus the TRANFORMS trial and a portion of the FREEDOMS-II trial will comprise the NDA/MAA package.) NVS – Albuferon: see HGSI.
ONTY – Phase-3 trial in Stage III NSCLC: first interim analysis (at 50% of deaths relative to trigger for final analysis): 2H10.
REGN - Rilonacept in flare prevention upon initiation of allopurinol - results expected in 2010 REGN - Rilonacept in flare treatment - results expected in 2010 REGN - Aflibercept in 3 different ph iii's (total enrollment expected is ~4000). VELOUR (2nd line colorectal + chemo cocktail), VITAL (2nd line NSCLC with docetaxel), VENICE (1st line HRPC with docetaxel + pred) REGN - VEGF Trap-Eye: results from ph-3 trials in AMD 4Q10.
Roche – ITMN-191 (a/k/a/ RG7127): phase-2b trial of SoC ± ITMN-191: RVR data from some arms 1Q10; report phase-1b data with ritonavir boosting early 2010. Roche – RG7128: phase-2b in geno-1 trial passed interim safety hurdle of first cohort 11/23/09, enrollment complete for second cohort late 1Q10. Start second (longer-duration) phase-2b in geno-1 1H10. Start separate phase-2b in geno-2/3 1H10. Roche – INFORM-n series of all-oral HCV trials: start INFORM-2 1Q10; start INFORM-3 (with SVR primary endpoint) 1H10.
SGP – Boceprevir NDA: 2011-2012.
TSPT – Intermezzo: FDA meeting scheduled for 1/20/10.
VRTX – Telaprevir phase-3 ADVANCE and ILLUMINATE trials in 1st-line setting: SVR data from ADVANCE in 2Q10 and from ILLUMINATE in 3Q10. VRTX – Telaprevir phase-3 REALIZE trial in 2nd-line setting: SVR data 3Q10. VRTX – Telaprevir NDA in first- and second-line settings: 4Q10. VRTX – Telaprevir ± VX-222: start phase-2 combo study 1Q10; report interim data (not SVR) mid 2010. VRTX – VX-509 JAK3 inhibitor: start 12-week phase-2 trial in RA 1Q10, interim data 2H10.
VRUS – RG7128 and INFORM-n series of trials: see Roche. VRUS – PSI-7851 pyrimidine-analog nuke: start phase 2a 1Q10; interim data 3Q10. VRUS – PSI-938 purine-analog nuke: file IND and start phase-1 1Q10, interim data 3Q10. VRUS – PSI-879 purine-analog nuke: file IND 4Q10.
ZGEN - Atacicept 48 week Ph ii in MS - clinicaltrials.org expects data 1H10
-- Procedure for Updating Calendar
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old calendar.
2. Make your additions or modifications, inserting new items in alphabetical order.
3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD IDIX MNTA”).
Market Data 
Markets 
AI
